Higher CXCL9 expression is associated with a worse prognosis in the HY, MF, and MY subgroups, but with a better prognosis in the PR and MS subgroups, indicating its dual role in MM progression. This evidence concerns the gene CXCL9 and Miyoshi myopathy.